Company / Operating Cash Flow
Charles River Laboratories Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$737.6M
FY2025
5-year range
$480.9M / $760.8M
FY2021-FY2025
Trend
+0.4%
vs FY2024
Sector context
#42 of 163
Health Care
What the data says
At $738M, Charles River Laboratories's operating cash flow ranks #42 of 163 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from $317M in FY2016 to $761M in FY2023.
Based on SEC 10-K filings.
$738M in FY2025 with a 5-year CAGR of +10.8%.
Declined from $761M to $738M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +10.5%
- 5-Year CAGR
- +10.8%
- 10-Year CAGR
- -
Sector benchmark
#42 of 163 in Health CareTop 26% of 163This company $737.6M Sector average $1.0B
▼
-29.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.8%, indicating consistent growth.
- In FY2025, operating cash flow increased 0.4% year-over-year.
- Ranks #42 out of 163 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $737.6M | +0.4% |
| FY2024 | $734.6M | -3.4% |
| FY2023 | $760.8M | +39.2% |
| FY2022 | $546.6M | +13.6% |
| FY2021 | $480.9M | +9.0% |
| FY2020 | $441.1M | +38.7% |
| FY2019 | $318.1M | -27.9% |
| FY2018 | $441.1M | +38.7% |
| FY2017 | $318.1M | +0.4% |
| FY2016 | $316.9M | +51.6% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026